Table 3A.
Effect of immunoglobulins from 38 PBC patients on mAChR3-activity on cholangiocytes (TFK-1-cells) before therapy and in the course without or with therapy.
| PBC patients | Effect on mAChR3-activity | |||
|---|---|---|---|---|
| None | Stimulatory | Inhibitory | ||
| Number (%) | ||||
| Without therapy (n = 4) |
Time point of diagnosis | 3 (75) | 0 | 1 (25) |
| After 9–177 months (median 103 months) | 2 (50) | 0 | 2 (50) | |
| UDCA-therapy (n = 18) | Before therapy | 0 | 0 | 18 (100) |
| Under therapy (12–206 months, median 121 months) | 4 (22) | 0 | 14 (78) | |
| Immunosuppressive therapy (n = 16) | Before therapy | 3 (19) | 2 (13) | 11 (69) |
| Under therapy (11–213 months, median 108 months) | 5 (31) | 0 | 11 (69) | |
Parenthesis reflects % patients' sera showing none, stimulatory, or inhibitory anti-mAChR3 reactivity. There were no significant differences between any of the groups.